ABCA1 Activators for ApoE4 Lipidation and Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and atherosclerosis, focusing on Aβ and tau pathological hallmarks, have not yielded clinically significant results, and existing ABCA1 activators, such as peptides and RXR/LXR ligands, face challenges in administration and specificity.
Innovation Solution
Development of low molecular weight, brain-permeable ABCA1 functional activators identified through phenotypic high-throughput screening and medicinal chemistry, which directly bind to the extracellular domain of ABCA1, increasing enzymatic activity and reversing hypo-lipidation of apoE4, thereby treating conditions associated with ABCA1 and apoE4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a 36-mer peptide ABCA1 agonist is used to reverse hypo-lipidation of apoE4, then the therapeutic effect on Alzheimer's disease is achieved, but the challenges in administration and limited bioavailability occur
Solution Approach 1:
The patent transforms the ABCA1 activator from a large 36-mer peptide to small molecular weight compounds (e.g., compounds of formula I with molecular weights typically below 500 Da). This parameter change in molecular size and structure fundamentally improves pharmacokinetic properties including bioavailability, blood-brain barrier penetration, and administration feasibility while preserving the ability to activate ABCA1 and reverse apoE4 hypo-lipidation
2Reliability
If an RXR/LXR ligand such as bexarotene is used to increase ABCA1 expression, then ABCA1 expression is upregulated, but a large number of additional genes are affected reducing specificity
Solution Approach 1:
The patent extracts and isolates the specific function of ABCA1 activation from the complex RXR/LXR receptor pathways. By designing small molecules that directly target and activate ABCA1 without requiring RXR/LXR ligand binding, the invention achieves selective ABCA1 upregulation without the broad gene expression changes and off-target effects associated with nuclear receptor ligands
Solution Approach 2:
The patent introduces small molecular weight compounds as direct intermediaries that bind to and activate ABCA1. These compounds serve as specific mediators between the therapeutic goal (increasing ABCA1 activity) and the molecular target, avoiding the need for complex nuclear receptor signaling pathways and their associated non-specific effects
3Ease of manufacture
If classical approaches focusing on Aβ and tau pathological hallmarks are used to treat Alzheimer's disease, then treatment strategies are developed, but clinically significant results are not achieved
Solution Approach 1:
Instead of directly targeting the pathological hallmarks (Aβ plaques and tau tangles), the patent inverts the therapeutic approach by targeting the upstream regulatory mechanism (ABCA1-mediated lipidation of apoE4). By reversing the hypo-lipidation of apoE4 through ABCA1 activation, the invention addresses the root cause that contributes to Aβ accumulation and tau pathology, rather than merely treating the downstream effects
Data Source
Figure 1~2
Figure 3A~3B
Figure 4~5
AI summary
The present invention relates to compounds that are functional activators of ATP binding cassette protein type 1 (ABCA1), and their use for treating diseases and conditions implicating ABCA1, including Alzheimer's Disease (AD) and atherosclerosis.